German pharmaceutical company Schering has received European Commission marketing approval for its radioimmunotherapy product Zevalin (ibritumomab tiuxetan), according to the Berlin-based firm.
Schering received the EU approval for the product to treat adult patients with rituximab relapsed or refractory CD20-positive follicular B-cell non-Hodgkin’s lymphoma. The firm plans to launch the product in Europe within the next few months, Schering said.
By AuntMinnie.com staff writers
January 22, 2004
Related Reading
Schering starts testing optical mammo, September 12, 2003
Currency effects weigh down Schering results, August 8, 2003
Epix, Schering to partner on MRI contrast, May 27, 2003
Schering diagnostics business dips in 2002, February 28, 2003
Peregrine, Schering team up, January 7, 2003
Copyright © 2004 AuntMinnie.com
